News | January 12, 2009

Micell Forms Alliance for the Development of Drug-Eluting Stents, Balloons

January 13, 2009 - Micell Technologies, a development-stage biomedical device company dedicated to developing innovative interventional cardiology systems, has obtained the rights to Maxcor's CE-marked Genius MAGIC Cobalt Chromium Coronary Stent System for the purpose of developing and marketing drug-eluting stents (DES) based on Micell's prop coating technology.

The companies also entered into an agreement to develop drug-eluting balloon (DEB) products for cardiovascular applications.

Micell has developed a drug-polymer formulation that is said to precisely and consistently control drug elution and the duration of polymer exposure. The coating has the potential to deliver a precise therapeutic solution for coronary artery disease without the long-term safety concerns of currently available DES. The in-licensing of the Genius MAGIC Cobalt Chromium Coronary Stent System provides what the company believes is the optimal bare-metal stent product for the further development of the company's drug-polymer coating. The company believes that DEB will advance the treatment of many clinical conditions while minimizing risks or side-effects of these treatments.

For more information: www.micell.com

Related Content

Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting| December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting| November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting| November 06, 2017
November 6, 2017 — Elderly patients undergoing...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting| November 03, 2017
November 3, 2017 — Biotronik's Orsiro...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting| November 01, 2017
OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual...
News | Stents Drug Eluting| October 25, 2017
Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at this year’s...
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Overlay Init